We performed an in vivo directed evolution capsid screen in non-human primates to identify novel capsids that target the back of the eye. This involved administering a diverse library of AAV capsid ...

LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings (MGTX) plc , a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster ...

Presenter: Alex Boyne, Gene Editing Platform Manager at CellectisSession Date/Time: May 9, 2024 at 12PM ETSession Title: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular ...

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings (MGTX) plc , a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...

Jeff Bartel is chairman and managing director of Hamptons Group, a private investment and strategic advisory firm headquartered in Miami. Gene editing technology, a major biotechnology advance, is ...

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Couragene, a genetic medicines company using novel delivery platforms, announces today that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University ...

LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit ...